AbbVie (NASDAQ:ABBV) had its target price boosted by Credit Suisse from $60.00 to $63.00 in a report issued on Wednesday. They currently have an outperform rating on the stock.AbbVie Inc. (NYSE:ABBV) shares moved down -0.21% in last trading session and ended the day at $55.75. ABBV Gross Margin is 76.40% and its return on assets is…
Timmins Gold Corp. (NYSEMKT:TGD) is aware that Sentry Investments intends to run a dissident slate to replace six of the eight existing members of the Timmins Gold board of directors (the “Board”). The Board is committed to considering the views of all of the shareholders of the Company and is confident that it can resolve…
Idera Pharmaceuticals Inc (NASDAQ:IDRA) announce plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan autoimmune diseases with high unmet clinical needs. Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock performance was 1.23% in last session and finished the day at $ 2.47. Traded volume…
Scientific Games Corporation (NASDAQ:SGMS), a leading diversified supplier of games and technology to the gaming and lottery industries, today reported financial results for the first quarter ended March 31, 2014. Scientific Games Corp (NASDAQ:SGMS) stock performance was -17.07% in last session and finished the day at $8.97. Traded volume was 7.44million shares in the last…
Corcept Therapeutics, Inc. (NASDAQ:CORT) entered into a manufacturing agreement (the “Agreement”) with AAIPharma Services Corp. (“AAI”), pursuant to which AAI will manufacture and package Korlym® tablets (the “product”). AAI will manufacture the product in accordance with FDA and other regulatory requirements. Corcept Therapeutics Incorporated (NASDAQ:CORT) stock performance was -6.85% in last session and finished the…
National Alliance Securities assumed coverage on shares of Teva Pharmaceutical Industries Ltd (ADR) (NASDAQ:TEVA) in a research note issued to investors on Monday, Analyst Ratings Netreports. The firm issued a buy rating and a $64.22 price target on the stock. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was -1.18% in last session and finished…
